Table 2.
Associations with overall survival and patient, tumor, and treatment characteristics
| No. (%) | Median surv, months | 2-year OS, % | 5-year OS, % | Univariate RR (95% CI) | P value | |
|---|---|---|---|---|---|---|
| Demographic | ||||||
| Age (year) | ||||||
| <70 | 645 (59.1) | 19.7 | 42.1 | 21.6 | 1.00 | |
| >70 | 447 (40.9) | 17.5 | 37.1 | 16.2 | 1.20 (1.05–1.37) | .008 |
| Gender | ||||||
| Female | 516 (47.3) | 19.5 | 40.9 | 18.3 | 1.00 | |
| Male | 576 (52.8) | 18.5 | 39.2 | 20.5 | 0.98 (0.85–1.12) | .730 |
| Treatment | ||||||
| Adjuvant treatment | ||||||
| None | 509 (46.6) | 15.5 | 34.6 | 16.1 | 1.00 | |
| Adjuvant CRT | 583 (53.4) | 21.1 | 44.7 | 22.3 | 0.73 (0.64–0.84) | <.001 |
| Surgery type | ||||||
| Class PD | 443 (40.6) | 19.7 | 40.2 | 22.5 | 1.00 | |
| PPPD | 585 (53.6) | 18.5 | 40.2 | 17.1 | 1.13 (0.98–1.30) | .093 |
| Classic/PP total panc | 64 (5.9) | 14.9 | 36.5 | 18.3 | 1.19 (0.89–1.60) | .228 |
| Tumor characteristics | ||||||
| Primary tumora | ||||||
| T1–2 | 254 (27.9) | 26.0 | 52.0 | 29.2 | 1.00 | |
| T3 | 657 (72.1) | 17.7 | 36.5 | 16.9 | 1.44 (1.21–1.70) | <.001 |
| Nodal status | ||||||
| N− | 354 (32.4) | 24.8 | 50.8 | 26.0 | 1.00 | |
| N+ | 738 (67.6) | 17.4 | 34.9 | 15.9 | 1.46 (1.26–1.69) | <.001 |
| Histologic grading | ||||||
| G1/2 | 489 (44.8) | 23.3 | 49.1 | 23.5 | 1.00 | |
| G3/4 | 603 (55.2) | 15.7 | 32.5 | 16.1 | 1.44 (1.26–1.65) | <.001 |
| Margin | ||||||
| Negative | 729 (66.8) | 21.0 | 45.3 | 22.9 | 1.00 | |
| Positive | 363 (33.2) | 15.1 | 29.5 | 12.7 | 1.47 (1.28–1.69) | <.001 |
PD pancreaticoduodenectomy, PP pylorus preserving, Total panc total pancreatectomy, N− node negative, N+ node positive, Surv survival, mo months, OS overall survival
aT-stage missing (n = 181) only among JHH patients